Thalidomide in hematologic malignancies: Future directions

Seminars in Hematology

Volumn 37, Issue 1 SUPPL. 3, 2000, Pages 35-39

  Alexanian, Raymond ^a,b,c,d   Anderson, Kenneth C ^a,b   Barlogie, Bart ^a,b,c,d   Stirling, David I ^a,b,c,d   Thomas, Deborah A ^a,b,c,d  

^a UNIVERSITY OF TEXAS   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOTOXIC AGENT; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 0034103606     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(00)90081-7     Document Type: Article

References (42)

1. KC Anderson JA Lust Role of cytokines in multiple myeloma Semin Hematol 36 1999 14 20 (suppl 3)
2. GJ Morgan Advances in the biology and treatment of myeloma Br J Haematol 105 suppl 1 1999 4 6
3. ML Varterasian Advances in the biology and treatment of multiple myeloma Curr Opin Oncol 11 1999 3 8
4. B Barlogie S Jagannath KR Desikan Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 93 1999 55 65
5. B Barlogie S Jagannath DH Vesole Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma Blood 89 1997 789 793
6. B Barlogie R Desikan D Spoon Tandem transplants (TAT) in over 1,000 patients with multiple myeloma (MM)—Inferior prognosis with chromosome 13 deletion Proc Am Soc Clin Oncol 18 1999 5a (abstr)
7. SV Rajkumar T Leong R Fonesca Bone marrow angiogenesis has prognostic value in multiple myeloma: An Eastern Cooperative Oncology Group study Proc Am Soc Clin Oncol 18 1999 19a (abstr)
8. R Alexanian M Dimopoulos The treatment of multiple myeloma N Engl J Med 330 1994 484 489
9. T Boehm J Folkman T Browder Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature 390 1997 404 407
10. Barlogie B, Desikan R, Munshi N, et al: Single course D.T. PACE anti-angiochemotherapy effects CR in plasma cell leukemia and fulminant multiple myeloma (MM). Blood 92:273b (suppl 1, abstr)
11. Y Kakeji BA Teicher Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents Invest New Drugs 15 1997 39 48
12. M Nguyen C Tran S Barsky Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies Int J Oncol 10 1997 965 969
13. BA Teicher SA Holden G Ara Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents Int J Cancer 57 1994 920 925
14. BH Bochner RJ Cote N Weidner Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis J Natl Cancer Inst 87 1995 1603 1612
15. G Fontanini M Lucchi S Vignati Angiogenesis as a prognostic indicator of survival in nonsmall-cell lung carcinoma: A prospective study J Natl Cancer Inst 89 1997 881 886
16. R Heimann D Ferguson C Powers Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer J Natl Cancer Inst 88 1996 1764 1769
17. P Viens J Jacquemier VJ Bardou Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy Breast Cancer Res Treat 54 1999 205 212
18. N Munshi CS Wilson J Penn Bone marrow neo-angiogenesis in multiple myeloma predicts poor prognosis Proc Am Soc Clin Oncol 18 1999 18a (abstr)
19. SV Rajkumar R Fonesca TE Witzig Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma Leukemia 13 1999 469 472
20. AX Zhu M Fleisher R Niesvizky Elevated serum concentrations of fibroblast growth factor (FGF) in multiple myeloma (MM) Proc Am Soc Clin Oncol 18 1999 41a (abstr)
21. BGM Durie SE Salmon A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer 36 1975 842 854
22. 2 microglobulin in myeloma: A Southwest Oncology Group study Blood 75 1990 823 830
23. 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma Blood 72 1988 219 223
24. 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma Blood 81 1993 3382 3387
25. GB Zulian Multiple myeloma: Clinical evaluation of plasma cell lymphoproliferative disorders and initial management Semin Hematol 34 1997 29 39 (suppl 1)
26. G Tricot B Barlogie S Jagannath Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities Blood 86 1995 4250 4256
27. G Tricot JR Sawyer S Jagannath Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants J Clin Oncol 15 1997 2659 2666
28. T Eisen C Boshoff MM Vaughan Antiangiogenic treatment of metastatic melanoma, renal cell, ovarian and breast cancers with thalidomide: A phase II study Proc Am Soc Clin Oncol 17 1998 441a (abstr)
29. WD Figg R Bergan O Brawley Randomized phase II study of thalidomide in androgen-independent prostate cancer (AIPC) Proc Am Soc Clin Oncol 16 1997 333a (abstr)
30. HA Fine JS Loeffler A Kyritsis A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas Proc Am Soc Clin Oncol 16 1997 385a (abstr)
31. G Long J Vredenburgh DA Rizzieri Pilot trial of thalidomide post-autologous peripheral blood progenitor cell transplantation (PBPC) in patients with metastatic breast cancer Proc Am Soc Clin Oncol 17 1998 181a (abstr)
32. GM Marx JA Levi DR Bell A phase I/II trial of thalidomide as an antiangiogenic agent in the treatment of advanced cancer Proc Am Soc Clin Oncol 18 1999 454a (abstr)
33. S Singhal J Mehta P Eddlemon Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM) Blood 92 suppl 1 1998 318a abstr
34. DE Bergsagel AJ Bailey GR Langley The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia N Engl J Med 301 1979 743 748
35. YW Huang A Hamilton OJ Arnuk Current drug therapy for multiple myeloma Drugs 57 1999 485 506
36. MM Oken Standard treatment of multiple myeloma Mayo Clin Proc 69 1994 781 786
37. J Ashby H Tinwell RD Callander Thalidomide: Lack of mutagenic activity across phyla and genetic endpoints Mutat Res 396 1997 45 64
38. X Zhu YP Zhang G Klopman Thalidomide and metabolites: Indications of the absence of ‘genotoxic’ carcinogenic potentials Mutat Res 425 1999 153 167
39. M Carlesimo S Giustini A Rossi Treatment of cutaneous and pulmonary sarcoidosis with thalidomide J Am Acad Dermatol 32 1995 866 869 (pt 2)
40. L Rousseau M Beylot-Barry M-S Doutre Cutaneous sarcoidosis successfully treated with low doses of thalidomide Arch Dermatol 134 1998 1045 1046
41. B Barlogie Advances in therapy of multiple myeloma: Lessons from acute leukemia Clin Cancer Res 3 1997 2605 2613
42. KC Anderson TJ Hamblin A Traynor Management of multiple myeloma today Semin Hematol 36 1999 3 8 (suppl 3)